Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115088
Chunk: 2

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 2
---
 presented in the prospectus forming a part of this Post-Effective Amendment No. 2 reflects the completion of the reverse stock split. The Company’s historical financial statements included in this prospectus do not reflect the reverse stock split.

The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

<div align='center'>PRELIMINARY — SUBJECT TO COMPLETION, DATED MAY 7, 2025</div>

PRELIMINARY PROSPECTUS

<div align='center'>**SCILEX HOLDING

COMPANY

Up to 6,685,714 Shares of Common

Stock**</div>

This prospectus relates to the resale from time to time by the selling stockholder named in this prospectus (including its permitted transferees, donees, pledgees and other successors-in-interest) (the “Selling Stockholder”) of up to an aggregate of 6,685,714 shares of our common stock, par value $0.0001 per share (“Common Stock”), consisting of (i) up to 6,500,000 shares of Common Stock issuable upon exercise of Penny Warrants (as defined below) (such shares issuable upon exercise, the “Penny Warrant Shares”), issued to Oramed Pharmaceuticals Inc. (“Oramed”) pursuant to the Scilex-Oramed SPA (as defined and described below) and (ii) up to 185,714 shares of Common Stock previously issued to Oramed upon exercise of a portion of the Penny Warrants previously issued to Oramed pursuant to the Scilex-Oramed SPA (the “Issued Shares” and together with the Penny Warrant Shares, the “Resale Shares”).

On September 21, 2023 (the “Oramed Closing Date”), we entered into, and consummated the transactions contemplated by that certain Securities Purchase Agreement, dated as of such date, between us and Oramed (the “Scilex-Oramed SPA”). Pursuant to the Scilex-Oramed SPA, among other things, on September 21, 2023, we (i) issued to Oramed (A) a senior secured promissory